A new Prostate Cancer Surrogate Marker-Vimentin3?
Volume 4 - Issue 3
Barbara Köditz1*, Andreas Stog1, Heike Göbel2, Manuel Huerat Arana1, Jochen WU Fries1, Axel Heidenreich1,3,
Melanie von Brandenstein1
- 1Faculity of Medicine and University Hospital of Cologne, Department of Urology, Germany
- 2Faculity of Medicine and University Hospital of Cologne, Insitute of Pathology, Germany
- 3Department of Urology, Medical University Vienna, Austria
Received:March 11, 2021 Published: April 21, 2021
Corresponding author: Barbara Köditz, Faculity of Medicine and University Hospital of Cologne, Department of Urology, Kerpener
Straße 62, 50937 Cologne, Germany
DOI: 10.32474/OAJOM.2021.04.000189
Fulltext
PDF
To view the Full Article Peer-reviewed Article PDF
Abstract
Background: Vimentin3 (Vim3) was recently described as a tumor marker for the direct differentiation between benign and
malignant kidney tumors. Our group recently reported correlation between Vim3 overexpression and increasing migration of PCa
cell lines.
Objectives: Comparing Vim3 serum levels among different PCa grades.
Design Setting and Participants: serum samples obtained. from PCa patients (n=314) between 2017 and 2020 were classified
according to the grade group system and analysed by ELISA, and Western Blot to measure Vim3 levels. Additionally, Paraffin
embedded human PCa samples from radical prostatectomy specimens were stained immunohistochemically for Vim3 (n=10).
Outcome Measurements and Statistical Analysis: Vim3 levels in serum samples show a correlation with increasing aggressiveness
of PCas. ANOVA analysis was used.
Results and limitations: the Vim3 protein level increased significantly (p<0.001) with increasing biological aggressiveness of
human PCa specimens from prostate biopsies and/or radical prostatectomy specimens (Gleason ≥8). A “grey-zone” value for Vim3
was determined (300-350 ng/ml). Furthermore, Vim3 levels in the Gleason >7 group (3+4) (4+3), metastasis, castration resistant
and castration responder was analysed. Vim3 levels significantly decrease in the group of ADT responders. Limitations include the
retrospective and single centre design.
Conclusion: Vim3 could be a new surrogate biomarker for the classification and graduation of PCa, especially for PCa with
increasing metastatic potential. Additionally, we hypothesised that Vim3 determination can be usable for ADT respond control.
Patient Summary: Serum Vim3 levels rise with increasing malignancy of the prostate cancer and correlate with the Gleason Score
and therefore could be usable
Abstract|
Introduction|
Materials and Methods|
Statistics|
Results|
Discussion|
Conclusions|
References|